CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy.

MLA

Yan, Yiyi, et al. “CX3CR1 Identifies PD-1 Therapy-Responsive CD8+ T Cells That Withstand Chemotherapy during Cancer Chemoimmunotherapy.” JCI Insight, vol. 3, no. 8, Apr. 2018. EBSCOhost, https://doi.org/10.1172/jci.insight.97828.

APA

Yan, Y., Cao, S., Liu, X., Harrington, S. M., Bindeman, W. E., Adjei, A. A., Jang, J. S., Jen, J., Li, Y., Chanana, P., Mansfield, A. S., Park, S. S., Markovic, S. N., Dronca, R. S., & Dong, H. (2018). CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight, 3(8). https://doi.org/10.1172/jci.insight.97828

Chicago

Yan, Yiyi, Siyu Cao, Xin Liu, Susan M Harrington, Wendy E Bindeman, Alex A Adjei, Jin Sung Jang, et al. 2018. “CX3CR1 Identifies PD-1 Therapy-Responsive CD8+ T Cells That Withstand Chemotherapy during Cancer Chemoimmunotherapy.” JCI Insight 3 (8). doi:10.1172/jci.insight.97828.